Chapter Three - Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912818" target="_blank" >RIV/00216208:11120/17:43912818 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/17:10364915 RIV/00216208:11150/17:10364915 RIV/00179906:_____/17:10364915 RIV/00064173:_____/17:N0000184 RIV/00064203:_____/17:10364915
Result on the web
<a href="https://doi.org/10.1016/bs.ircmb.2016.09.003" target="_blank" >https://doi.org/10.1016/bs.ircmb.2016.09.003</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/bs.ircmb.2016.09.003" target="_blank" >10.1016/bs.ircmb.2016.09.003</a>
Alternative languages
Result language
angličtina
Original language name
Chapter Three - Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents
Original language description
Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
International Review of Cell and Molecular Biology; Vol. 330
ISBN
978-0-12-812467-3
Number of pages of the result
42
Pages from-to
115-156
Number of pages of the book
352
Publisher name
Academic Press
Place of publication
Cambridge
UT code for WoS chapter
000452397000003